Naturally Occurring Canine Angiosarcoma as a Translational Model for Human Angiosarcoma
Official title: Naturally Occurring Canine Hemangiosarcoma as a Translational Model for Angiosarcoma
Funded at University of Florida · NIH-11343984 · Data updated 2026-11-12
Researchers are studying naturally occurring canine angiosarcoma to inform how human angiosarcoma could be better understood and treated.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | June 3, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $635,324 |
| NIH project number | 1R01CA310992-01 |
| Project ID | NIH-11343984 on NIH RePORTER |
Who could benefit from this research
✓Could help
Humans and dogs with angiosarcoma or related vascular cancers; primarily focusing on canine models to inform human disease.
✕Less likely to help
People without angiosarcoma or without access to related translational research resources are unlikely to benefit directly.
What this research studies
This project uses dogs with naturally arising angiosarcoma to develop and validate translational animal models that reflect human disease. Researchers will integrate AI-driven analyses and PI3K pathway insights to enhance modeling accuracy and predictive value for human angiosarcoma. The goal is to create more reliable preclinical tools that can guide future therapies and improve translation from animal models to patient care.
Why it matters
Potential benefit: If successful, the work could lead to better animal models that predict how human angiosarcoma responds to treatments, accelerating the development of targeted therapies for patients.
How similar studies have gone: Previous work has shown that canine angiosarcoma models can mirror human disease features and support translational research.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Kim, Jong Hyuk — University of Florida
- Study coordinator: Kim, Jong Hyuk
Related research
Other NIH-funded projects on the same topics.
-
Personalised neoadjuvant therapy planning for adults with high‑risk soft tissue sarcoma
This project tests whether analyzing tumor tissue and clinical data can help guide neoadjuvant chemotherapy decisions for adults with high‑risk soft tissue sarcomas.
-
VO plus pembrolizumab for angiosarcoma
This study tests whether injecting Vusolimogene Oderparepvec (VO) into tumors, together with pembrolizumab, can help people with advanced angiosarcoma who have already tried other immunotherapies.
-
Combining immune therapy with chemotherapy for advanced soft tissue sarcoma
This study is testing if combining a new immune therapy with standard chemotherapy can help people with advanced soft tissue sarcoma who can’t have surgery or radiation feel better and live longer.
-
Evaluating AGX101 for advanced solid tumors
This study is testing a new drug called AGX101 to see if it can help people with advanced solid tumors who haven't had success with other treatments.
-
Observational study of localized angiosarcoma
This study is trying to find the best ways to treat localized angiosarcoma by looking at how patients are managed across different hospitals in Italy.
-
MASCT-I plus doxorubicin and ifosfamide as first-line treatment for advanced soft tissue sarcoma
This trial will test whether adding MASCT-I to standard chemotherapy (doxorubicin and ifosfamide) helps adults with advanced soft tissue sarcoma respond better or live longer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.